avadomide   Click here for help

GtoPdb Ligand ID: 10522

Synonyms: CC-122 | CC122 | Compound A [WO2014039960A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Avadomide (CC-122) is a cereblon (CRBN)-targeting compound [2] that exhibits potent single-agent clinical antitumour and immunomodulatory activities [3]. It retains the glutarimide moiety that is shared by all thalidomide family drugs, and which is known to directly interact with CRBN. The INN record specifies avadomide as a racemic mixture of enantiomers. We show the structure without specified stereochemistry to represent the mixture. It is claimed as Compound A in Celgene's patent WO2014039960A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 107.08
Molecular weight 286.11
XLogP -0.04
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C1CCC(C(=O)N1)n1c(C)nc2c(c1=O)c(N)ccc2
Isomeric SMILES O=C1CCC(C(=O)N1)n1c(C)nc2c(c1=O)c(N)ccc2
InChI InChI=1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)
1. Gandhi A, Dimartino J, Chopra R. (2014)
Methods for the treatment of locally advanced breast cancer.
Patent number: WO2014039960A1. Assignee: Celgene Corporation. Priority date: 10/09/2012. Publication date: 13/03/2014.
2. Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E et al.. (2015)
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Blood, 126 (6): 779-89. [PMID:26002965]
3. Rasco DW, Papadopoulos KP, Pourdehnad M, Gandhi AK, Hagner PR, Li Y, Wei X, Chopra R, Hege K, DiMartino J et al.. (2019)
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
Clin Cancer Res, 25 (1): 90-98. [PMID:30201761]